Blog

Eye cancer, also known as ocular cancer, refers to a group of rare but potentially serious malignancies that develop within the eye or its surrounding structures. While uncommon, eye cancer presents unique clinical challenges due to its impact on vision, complex anatomy and potential for metastasis. For healthcare professionals, sponsors and clinical research organisations (CROs), […]

Cancer remains one of the most complex and challenging areas of modern medicine, driving continuous innovation in drug development. At the heart of this progress are oncology clinical trials, which play a critical role in advancing new therapies and improving patient outcomes. For biotech and pharmaceutical companies, these trials are not only a regulatory requirement […]

Phase 1 trials are the first clinical trials to include humans. They are essential in determining the safety and tolerability of a drug in development. A well-designed phase 1 clinical trial is heavily dependent on clinical pharmacology, the medical discipline that bridges preclinical science into data-driven decisions. Without thorough clinical pharmacology, Phase 1 clinical trials […]

What is a primary immunodeficiency? A primary immunodeficiency is an umbrella term for a group of conditions that hinder the body’s ability to fight infection. Sometimes referred to as a primary immune disorder, primary immunodeficiency is a group of over 550 chronic, inborn genetic conditions. Whilst in most circumstances they are genetically inherited, some symptoms […]

Brain tumours present a significant challenge in oncology, particularly in their malignant forms, where treatment options remain limited and outcomes can be poor. Despite ongoing advances in research, there is still a critical need to improve how these conditions are identified, understood and treated. Recognising the symptoms of brain tumours and understanding the different types […]

Rare Disease Day 2026, observed on 28 February, highlights the ongoing need to improve access to timely diagnosis, effective treatment, and appropriate care for people living with rare and ultra rare diseases. Marked annually on the last day of February, the campaign brings together patients, clinicians, researchers, and policymakers to address the systemic challenges that […]